Alps Advisors Inc. Increases Holdings in Exelixis, Inc. (EXEL)

Alps Advisors Inc. boosted its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 9.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 31,561 shares of the biotechnology company’s stock after acquiring an additional 2,691 shares during the quarter. Alps Advisors Inc.’s holdings in Exelixis were worth $621,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Cornerstone Advisors Inc. acquired a new stake in shares of Exelixis during the 4th quarter valued at about $38,000. Financial Gravity Companies Inc. bought a new position in Exelixis in the 4th quarter worth approximately $50,000. IFP Advisors Inc increased its position in Exelixis by 188.2% in the 4th quarter. IFP Advisors Inc now owns 4,237 shares of the biotechnology company’s stock worth $82,000 after buying an additional 2,767 shares during the period. Rehmann Capital Advisory Group increased its position in shares of Exelixis by 1,417.1% during the third quarter. Rehmann Capital Advisory Group now owns 8,966 shares of the biotechnology company’s stock valued at $506,000 after purchasing an additional 8,375 shares during the period. Finally, Polaris Greystone Financial Group LLC bought a new stake in shares of Exelixis during the third quarter valued at approximately $177,000. Hedge funds and other institutional investors own 78.28% of the company’s stock.

EXEL has been the topic of several recent analyst reports. Oppenheimer set a $40.00 price target on Exelixis and gave the company a “buy” rating in a research note on Thursday, November 1st. BidaskClub raised Exelixis from a “sell” rating to a “hold” rating in a research note on Saturday, December 1st. ValuEngine lowered Exelixis from a “hold” rating to a “sell” rating in a research note on Saturday, January 19th. Zacks Investment Research downgraded Exelixis from a “buy” rating to a “hold” rating in a report on Monday. Finally, TheStreet upgraded Exelixis from a “c+” rating to a “b-” rating in a report on Monday, December 17th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and seven have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $27.25.

In related news, Director George A. Scangos sold 40,000 shares of the company’s stock in a transaction that occurred on Friday, February 1st. The stock was sold at an average price of $23.53, for a total value of $941,200.00. Following the transaction, the director now owns 1,363,031 shares in the company, valued at $32,072,119.43. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Patrick J. Haley sold 1,560 shares of the company’s stock in a transaction that occurred on Wednesday, January 9th. The shares were sold at an average price of $23.50, for a total value of $36,660.00. The disclosure for this sale can be found here. Insiders have sold a total of 337,807 shares of company stock valued at $7,248,232 over the last three months. Corporate insiders own 4.80% of the company’s stock.

NASDAQ EXEL opened at $22.05 on Thursday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.54 and a current ratio of 8.66. Exelixis, Inc. has a twelve month low of $13.42 and a twelve month high of $30.24. The firm has a market cap of $6.44 billion, a P/E ratio of 43.24, a PEG ratio of 1.34 and a beta of 2.21.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Tuesday, February 12th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.23 by $0.14. The company had revenue of $228.60 million for the quarter, compared to the consensus estimate of $188.44 million. Exelixis had a return on equity of 55.71% and a net margin of 49.53%. The firm’s revenue was up 90.4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.12 EPS. On average, analysts forecast that Exelixis, Inc. will post 1.3 earnings per share for the current fiscal year.

WARNING: This story was originally posted by Community Financial News and is the property of of Community Financial News. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.com-unik.info/2019/02/14/alps-advisors-inc-increases-holdings-in-exelixis-inc-exel.html.

About Exelixis

Exelixis, Inc, a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

Featured Story: Google Finance Portfolio Tips and Tricks

Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL).

Institutional Ownership by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit